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Abstract: Cross-linking of antigen-specific IgE bound to the high-affinity IgE receptor (FcεRI) on the
surface of mast cells with multivalent antigens results in the release of mediators and development
of type 2 inflammation. FcεRI expression and IgE synthesis are, therefore, critical for type 2
inflammatory disease development. In an attempt to clarify the relationship between eosinophilic
chronic rhinosinusitis (ECRS) and mast cell infiltration, we analyzed mast cell infiltration at lesion
sites and determined its clinical significance. Mast cells are positive for c-kit, and IgE in uncinated
tissues (UT) and nasal polyps (NP) were examined by immunohistochemistry. The number of positive
cells and clinicopathological factors were analyzed. Patients with ECRS exhibited high levels of
total IgE serum levels and elevated peripheral blood eosinophil ratios. As a result, the number of
mast cells with membranes positive for c-kit and IgE increased significantly in lesions forming NP.
Therefore, we classified IgE-positive mast cells into two groups: membrane IgE-positive cells and
cytoplasmic IgE-positive cells. The amount of membrane IgE-positive mast cells was significantly
increased in moderate ECRS. A positive correlation was found between the membrane IgE-positive
cells and the radiological severity score, the ratio of eosinophils, and the total serum IgE level.
The number of cytoplasmic IgE-positive mast cells was significantly increased in moderate and
severe ECRS. A positive correlation was observed between the cytoplasmic IgE-positive cells and the
radiological severity score, the ratio of eosinophils in the blood, and the total IgE level. These results
suggest that the process of mast cell internalization of antigens via the IgE receptor is involved in
ECRS pathogenesis.
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1. Introduction
Chronic rhinosinusitis (CRS) is a condition characterized by chronic mucosal inflammation in
paranasal sinuses for more than 12 weeks, which ultimately causes nasal obstruction, rhinorrhea,
and posterior nasal discharge. CRS is a disease with various etiologies and pathologies and is often
accompanied by headaches and olfactory disorders. One type of CRS is refractory eosinophilic chronic
rhinosinusitis (ECRS). Many patients with non-ECRS are cured by antibiotic administration or surgery.
However, ECRS forms multiple nasal polyps (NP) in a bilateral nature and tends to relapse even after
surgery [1,2]. This disease is relieved by steroid administration, and steroid therapy is considered to
be the most effective treatment [3,4]. ECRS lesions are characterized by an infiltration of numerous
eosinophils. Furthermore, in these patients, increases in peripheral blood allergic factors are observed,
including an increase in eosinophils and IgE. Additionally, this disease frequently occurs in patients
with aspirin intolerance, in which aspirin causes asthma [5].
Mast cells have a wide variety of functional molecules expressed on their surface, which facilitate
cell activation via chemical mediators that synthesize and secrete various cytokines during allergic or
innate immune responses, both of which are heavily influenced by the involvement of the acquired
immune system [6–8]. Mast cells have also been shown to interact with immune cells, such as T-cells,
B-cells, and dendritic cells, and to participate in transplant rejection and tumor immunity [9,10] while
also assisting in protection against viral and bacterial infection via Toll-like receptors (TLRs) [11,12].
Regarding allergies, it has been confirmed that mast cells interact with B-cells in the nasal mucosa
and bronchial mucosa at the time of allergic inflammation leading to the promotion of local IgE
production, suggesting the existence of an allergic exacerbation cycle [13]. Further, mast cells activated
by local inflammation express CD40L (CD154) and produce Th2 cytokines such as interleukin (IL)-4
and IL-13. It has also been shown that IgE production is induced by co-culturing nasal mucosal
mast cells from allergic rhinitis patients with B-cells in vitro [13]. This IgE produced in inflamed
regions serves to enhance high-affinity IgE receptor (FcεRI) expression on the surface of mast cells
and markedly increases sensitivity to this antigen [14]. Thus, it seems that the allergic exacerbation
cycle, responsible for further promoting the inflammatory response, will be initiated in the local
area of allergic inflammation. Herein, we focused on the fact that many patients with ECRS had a
predisposition to allergies, and thus, the current study sought to investigate mast cell expression and
its clinical significance in ECRS lesions.
2. Results
2.1. Patients’ Characteristics
Clinical features are shown in Table 1. Prior to surgery, each CRS patient was examined for serum
levels of IgE, eosinophil ratio, and 1-s forced expiratory volume/forced vital capacity (FEV1/FVC)
ratio. Serum IgE levels were found to be high in severe cases of ECRS (median; 476.2 IU/mL, n = 10),
while moderate and severe ECRS cases showed an increased eosinophil count in the peripheral blood.
Specifically, the mean blood eosinophil ratio was 5.6% for moderate ECRS and 10.8% for severe ECRS.
Further, the mean cognitive threshold in the baseline olfactory examination was particularly high in
patients with ECRS. Among 71 CRS patients, 57 patients exhibited nasal polyps (CRSwNP), with the
remainder exhibiting no visible NP in the middle meatus (CRSsNP; n = 14). Samples were divided into
six groups according to the CRS phenotype: uncinated process tissues (UT) from non-CRS (n = 13), UT
from CRSsNP (n = 14), NP from non-ECRS (n = 27), NP from mild ECRS (n = 8), NP from moderate
ECRS (n = 12), and NP from severe ECRS (n = 10) (Figure 1).
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Table 1. Subjects’ characteristics.
Groups Non-CRS(UT)
CRSsNP
(UT)
Non-ECRS
(NP)
Mild ECRS
(NP)
Moderate
ECRS (NP)
Severe ECRS
(NP)
Number 13 14 27 8 12 10
Age (years old) 61.4 (41–92) 60.5 (35–75) 57.6 (36–84) 56.8 (34–70) 52.5 (32–78) 49.5 (33–74)
Sex (female/male) 9/4 6/8 8/19 2/6 5/7 3/7
Blood eosinophil rate (%) 2.1 (0–5.9) 2.5 (0.8–8.6) 3.2 (0.1–7.3) 3.8 (2.6–4.7) 5.6 (1.7–7.9) 10.8 (4.6–22.8)
Serum total IgE (IU/mL) 34.5 (2–99) 141.7 (4–923) 164.6 (4–1322) 150.4 (10–452) 256.4 (34–1768) 476.2 (34–1899)
FEV1/FVC ratio (%) 83.8 (68.7–92.7) 77.3 (66.5–84.7) 78.3 (47.2–91.9) 76.3 (73.2–86.4) 76.0 (49.2–92.3) 72.8 (52.6–89.5)
CT grading score
(Lund–Mackay) 1.9 (1–3) 6.5 (1–14) 13.4 (3–24) 14.3 (8–22) 13.4 (7–21) 16.6 (10–24)
Comorbidity of asthma (n) 0 0 5 0 5 10
Comorbidity of NSAIDs
intolerance (n) 0 0 2 0 1 3
CRS, chronic rhinosinusitis; ECRS, eosinophilic chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal
polyps; UT, uncinated tissues; NP, nasal polyps; FEV1/FVC ratio, 1-s forced expiratory volume/forced vital capacity
ratio; NSAIDs, nonsteroidal anti-inflammatory drugs.Int. J. Mol. Sci. 2020, 19, x  3 of 14 
 
Figure 1. Histological  findings of non‐chronic  rhinosinusitis  (CRS), CRS, and eosinophilic chronic 
rhinosinusitis (ECRS). Hematoxylin and eosin  staining at 400 magnification  (high‐powered  field, 
HPF). (A) non‐CRS, (B) CRS with no visible NP in the middle meatus (CRSsNP), (C) non‐ECRS, (D) 
mild ECRS, (E) moderate ECRS, and (F) severe ECRS. In ECRS, infiltration of eosinophils under the 
mucosa was observed. 
2.2. Histological Evaluation and Pathophysiological Significance of c‐Kit‐Positive Cells 
The  c‐kit‐positive mast  cells were  observed  in  each  group  (Figure  2), with  the  number  of 
c‐kit‐positive cells in UT and NP ranging from 0–18 (median: 5.3 cells/HPF) and from 2–36 (median: 
9.6  cells/HPF),  respectively,  per  high‐power  field  (HPF).  The  number  of  c‐kit‐positive  cells was 
significantly higher in NP than in UT (p < 0.001; Figure 3A), which was then compared between the 
six study groups. No significant differences were observed between the UT from the non‐CRS group 
and the CRSsNP group; however, the c‐kit‐positive cells were significantly increased in the groups 
forming NP as compared to CRSsNP. The Kruskal–Wallis test revealed a significant difference in the 
number of infiltrating c‐kit‐positive cells among these groups (p < 0.0001). However, no significant 
difference was observed between non‐ECRS and each ECRS group. In addition, the severity of ECRS 
and the number of c‐kit‐positive cells were not directly related. 
 
Figure 1. Histological findings of non-chronic rhinosinusitis (CRS), CRS, and eosinophilic chronic
rhinosinusitis (ECRS). Hematoxylin and eosin staining at 400× magnification (high-powered field,
HPF). (A) non-CRS, (B) CRS with no visible NP in the middle meatus (CRSsNP), (C) non-ECRS, (D)
mild ECRS, (E) moderate ECRS, and (F) severe ECRS. In ECRS, infiltration of eosinophils under the
mucosa was observed.
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2.2. Histological Evaluation and Pathophysiological Significance of c-Kit-Positive Cells
The c-kit-positive mast cells were observed in each group (Figure 2), with the number of
c-kit-positive cells in UT and NP ranging from 0–18 (median: 5.3 cells/HPF) and from 2–36 (median:
9.6 cells/HPF), respectively, per high-power field (HPF). The number of c-kit-positive cells was
significantly higher in NP than in UT (p < 0.001; Figure 3A), which was then compared between the six
study groups. No significant differences were observed between the UT from the non-CRS group and
the CRSsNP group; however, the c-kit-positive cells were significantly increased in the groups forming
NP as compared to CRSsNP. The Kruskal–Wallis test revealed a significant difference in the number of
infiltrating c-kit-positive cells among these groups (p < 0.0001). However, no significant difference was
observed between non-ECRS and each ECRS group. In addition, the severity of ECRS and the number
of c-kit-positive cells were not directly related.Int. J. Mol. Sci. 2020, 19, x  4 of 14 
 
Figure 2.  Immunohistochemical staining of c‐kit  in the diseased tissue. (A) non‐CRS,  (B) CRSsNP, 
(C) non‐ECRS, (D) mild ECRS, (E) moderate ECRS, and (F) severe ECRS. The surface membrane of 
mast cells was positive for c‐kit (400 magnification). 
Next, we  pathophysiologically  characterized  the  degree  of  c‐kit‐positive  cell  infiltration  in 
sinonasal  tissues. A significant positive correlation was  found between  the number of  infiltrating 
c‐kit‐positive cells and the radiological severity of CRS (r = 0.309, p = 0.006; Figure 3B). Conversely, 
no correlation was observed between the number of  infiltrating c‐kit‐positive cells and peripheral 
blood eosinophilia (r = 0.123, p = 0.265; Figure 3C) or total serum IgE level (r = 0.043, p = 0.710; Figure 
3D). 
 
Figure 2. Immunohistochemical staining of c-kit in the diseased tissue. (A) non-CRS, (B) CRSsNP, (C)
non-ECRS, (D) mild ECRS, (E) moderate ECRS, and (F) severe ECRS. The surface membrane of mast
cells was positive for c-kit (400× magnification).
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Figure  3.  Lesion  infiltration  by  c‐kit‐positive  cells  and  the  number  of  c‐kit‐positive  cells.  (A) 
Examination  of  the  number  of  c‐kit  positive  cells  in  the  hotspot  of  each  case.  The  number  of 
c‐kit‐positive cells increased in the nasal polyp groups (p < 0.0001, Kruskal–Wallis test). Relationship 
between  the number of  c‐kit positive  cells and  the preoperative CT  score  (B),  eosinophil  ratio  in 
peripheral blood (C), and total serum IgE level (D). 
Table 1. Subjects’ characteristics. 
Groups  Non‐CRS   (UT) 
CRSsNP   
(UT) 
Non‐ECRS   
(NP) 
Mild ECRS   
(NP) 
Moderate ECRS 
(NP) 
Severe ECRS 
(NP) 
Number  13  14  27  8  12  10 
Figure 3. Lesion infiltration by c-kit-positive cells and the number of c-kit-positive cells. (A) Examination
of the number of c-kit positive cells in the hotspot of each case. The number of c-kit-positive cells
increased in the nasal polyp groups (p < 0.0001, Kruskal–Wallis test). Relationship between the number
of c-kit positive cells and the preoperative CT score (B), eosinophil ratio in peripheral blood (C), and
total serum IgE level (D).
Next, we pathophysiologically characterized the degree of c-kit-positive cell infiltration in sinonasal
tissues. A significant positive correlation was found between the number of infiltrating c-kit-positive
cells and the radiological severity of CRS (r = 0.309, p = 0.006; Figure 3B). Conversely, no corr lation
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was observed between the number of infiltrating c-kit-positive cells and peripheral blood eosinophilia
(r = 0.123, p = 0.265; Figure 3C) or total serum IgE level (r = 0.043, p = 0.710; Figure 3D).
2.3. Histological Evaluation and Pathophysiological Significance of IgE-Positive Cells
IgE-positive mast cells were observed in each group (Figure 4) and classified into two types: mast
cells that showed IgE-positive only in the membrane were termed “membrane IgE-positive mast cells”,
while mast cells with IgE positivity in the cytoplasm were designated “cytoplasmic IgE-positive mast
cells”. The number of each cell type was enumerated.Int. J. Mol. Sci. 2020, 19, x  7 of 14 
 
Figure 4. Immunohistochemical findings of IgE in the diseased tissue. (A) non‐CRS, (B) CRSsNP, (C) 
non‐ECRS, (D) mild ECRS, (E) moderate ECRS, and (F) severe ECRS. IgE‐positive cells increased in 
the diseased tissue (400 magnification). 
A  higher  number  of  membrane  IgE‐positive  mast  cells  was  observed  in  cases  with  NP 
compared to those without, with the numbers of membrane IgE‐positive mast cells in the UT and NP 
ranging from 0–16 (median: 5.2 cells/HPF) and from 0–27 (median: 9.5 cells/HPF), respectively, per 
HPF. The Kruskal–Wallis  test  further demonstrated  that,  although  the number was not different 
between UT from non‐CRS and UT from CRSsNP, membrane IgE‐positive mast cells  increased  in 
NP‐forming  groups.  In  addition,  moderate  ECRS  showed  a  statistically  significant  increase 
compared  to  non‐CRS  and CRSsNP  (UT  from  non‐CRS:  p  <  0.05; UT  from  non‐ECRS:  p  <  0.05) 
(Figure  5A).  However,  no  significant  difference  was  observed  between  non‐ECRS  and  ECRS. 
Furthermore,  comparing  the  clinical  data  with  membrane  IgE‐positive  cells  revealed  that  the 
number  of  membrane  IgE‐positive  mast  cells  was  also  positively  correlated  with  radiological 
severity of CRS (r = 0.470, p < 0.001; Figure 5B), peripheral blood eosinophilia (r = 0.327, p = 0.002; 
Figure 5C), and the total serum IgE level (r = 0.458, p < 0.001; Figure 5D). 
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higher number of me brane IgE-positive mast cells was observed in cases with NP compared
to those without, with the numbers of embrane IgE-positive mast cells in the UT and NP ranging
from 0–16 ( edian: 5.2 cells/HPF) and from 0–27 (median: 9.5 cells/HPF), respectively, per HPF.
The Kruskal–Wallis test further demonstrated that, although the number was not different between
UT from non-CRS and UT from CRSsNP, membrane IgE-positive mast cells increased in NP-forming
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groups. In addition, moderate ECRS showed a statistically significant increase compared to non-CRS
and CRSsNP (UT from non-CRS: p < 0.05; UT from non-ECRS: p < 0.05) (Figure 5A). However, no
significant difference was observed between non-ECRS and ECRS. Furthermore, comparing the clinical
data with membrane IgE-positive cells revealed that the number of membrane IgE-positive mast
cells was also positively correlated with radiological severity of CRS (r = 0.470, p < 0.001; Figure 5B),
peripheral blood eosinophilia (r = 0.327, p = 0.002; Figure 5C), and the total serum IgE level (r = 0.458,
p < 0.001; Figure 5D).Int. J. Mol. Sci. 2020, 19, x  8 of 14 
 
Figure 5. Lesion infiltration by membrane IgE‐positive cells and the number of IgE‐positive cells. (A) 
Determination of membrane  IgE‐positive  cell number  in  the hotspot of each case. The number of 
membrane  IgE‐positive cells  increased  in  the nasal polyp groups  (p < 0.0025, Kruskal–Wallis  test). 
Relationships between the number of membrane IgE‐positive cells and the preoperative CT score (B), 
eosinophil ratio in peripheral blood (C), and total serum IgE level (D). 
Furthermore, cytoplasmic IgE‐positive mast cells were found in lesions of moderate and severe 
ECRS (Figure 6A–F). The number of these cells was statistically higher in moderate and severe ECRS 
than in the other groups (p < 0.05 and p < 0.01, respectively; Figure 6G). The number of cytoplasmic 
IgE‐positive mast cells was also significantly correlated to radiological severity of CRS (r = 0.280, p = 
Figure 5. Lesion infiltration by membrane IgE-positive cells and the number of IgE-positive cells.
(A) Determination of membrane IgE-positive cell number in the hotspot of each case. The number
of membrane IgE-positive cells increased in the nasal polyp groups (p < 0.0025, Kruskal–Wallis test).
Relationships between the number of membrane IgE-positive cells and the preoperative CT score (B),
eosinophil ratio in peripheral blood (C), and total serum IgE level (D).
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Furthermore, cytoplasmic IgE-positive mast cells were found in lesions of moderate and severe
ECRS (Figure 6A–F). The number of these cells was statistically higher in moderate and severe ECRS
than in the other groups (p < 0.05 and p < 0.01, respectively; Figure 6G). The number of cytoplasmic
IgE-positive mast cells was also significantly correlated to radiological severity of CRS (r = 0.280,
p = 0.012; Figure 6H), peripheral blood eosinophilia (r = 0.404, p < 0.001; Figure 6I), and total serum
IgE (r = 0.500, p < 0.001; Figure 6J).
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Figure  6.  Lesion  infiltration  by  cytoplasmic  IgE‐positive  cells  in  each  lesion.  (A)  non‐CRS,  (B) 
CRSsNP, (C) non‐ECRS, (D) mild ECRS, (E) moderate ECRS, and (F) severe ECRS. (G) Cytoplasmic 
IgE‐positive mast cells were significantly  increased  in moderate and severe ECRS  lesions  (p < 0.05 
and p < 0.01, respectively). Relationships between the number of cytoplasmic IgE‐positive cells and 
the preoperative CT score (H), eosinophil ratio in peripheral blood (I), and total serum IgE level (J). 
3. Discussion 
In this study, an increase in mast cells was observed in non‐ECRS and ECRS lesions. Two types 
of human mast cells have been described: mast cells that express both tryptase and chymase, found 
in the subcutaneous connective tissue (TC‐type mast cells; MCTC), and mast cells that express only 
tryptase, found in the airway mucosa and intestinal mucosa (T‐type mast cells; MCT) [15]. Baba et al. 
reported increased numbers of MCTC in the epithelium, glands, and submucosa of ECRS polyps, as 
well  as  increased  numbers  of  MCT  in  the  glands  and  submucosa  of  non‐ECRS  polyps  [16]. 
Furthermore,  it  was  suggested  that  the  distribution  of  IgE‐positive  mast  cell  subtypes  differs 
between ECRS and non‐ECRS [16]. As the present study did not analyze production of tryptase and 
chymase,  it  is  unclear  which  type  of mast  cells  increased. However,  it  is  presumed  that  MCT 
increased with non‐ECRS and MCTC increased with ECRS. In our study, the number of c‐kit‐positive 
cells and the number of membrane IgE‐positive mast cells increased in cases where NP were formed. 
In  addition,  moderate  and  severe  ECRS  exhibited  an  increase  in  the  number  of  cytoplasmic 
IgE‐positive mast  cells. Mast  cell  endocytosis  is  caused  by  strong  antigen  stimulation  and  is  a 
phenomenon  in  which  FcεRI  and  IgE  antibodies  on  the  membrane  surface  are  taken  into  the 
cytoplasm. Mast cell endocytosis is considered to be the cause of positive cytoplasmic IgE. Increased 
levels of IgE are believed to increase the amount of FcεRI, which in turn induces increased levels of 
endocytosis  [17].  In  patients  with  ECRS,  IgE‐positive  cells  are  increased  due  to  an  allergic 
predisposition.  In  severe  cases  of  ECRS,  the  majority  of  patients  have  asthma,  and  excessive 
Figure 6. Lesion infiltration by cytoplasmic IgE-positive cells in each lesion. (A) non-CRS, (B) CRSsNP,
(C) non-ECRS, (D) mild ECRS, (E) moder te ECRS, and (F) sev re ECRS. (G) Cytoplasmic IgE-positive
mast cells were significantly increased in moderate and severe ECRS l sions (p < 0.05 and p < 0.01,
respectively). Relation hips between the number of cytoplasmic IgE-positi e c lls and the preoperative
CT score (H), eosinophi ratio in peripheral blood (I), and total serum IgE level (J).
3. Discussion
In this study, an increase in mast cells was observed in non-ECRS and ECRS lesions. Two types
of human mast cells have been described: mast cells that express both tryptase and chymase, found
in the subcutaneous connective tissue (TC-type mast cells; MCTC), and mast cells that express only
tryptase, found in the airway mucosa and intestinal mucosa (T-type mast cells; MCT) [15]. Baba
et al. reported increased nu bers of MCTC in the epithelium, glands, and submucosa of ECRS
polyps, as well as increased numbers of MCT in the glands and submucosa of non-ECRS polyps [16].
Furthermore, it was suggested that the distribution of IgE-positive mast cell subtypes differs between
ECRS and non-ECRS [16]. As the present study did not analyze production of tryptase and chymase,
it is unclear which type of mast cells increased. However, it is presumed that MCT increased with
non-ECRS and MCTC increased with ECRS. In our study, the number of c-kit-positive cells and the
number of membrane IgE-positive mast cells increased in cases where NP were formed. In addition,
moderate and severe ECRS exhibited an increase in the number of cytoplasmic IgE-positive mast cells.
Mast cell endocytosis is caused by strong antigen stimulation and is a phenomenon in which FcεRI
and IgE antibodies on the membrane surface are taken into the cytoplasm. Mast cell endocytosis is
considered to be the cause of positive cytoplasmic IgE. Increased levels of IgE are believed to increase
the amount of FcεRI, which in turn induces increased levels of endocytosis [17]. In patients with
ECRS, IgE-positive cells are increased due to an allergic predisposition. In severe cases of ECRS, the
majority of patients have asthma, and excessive endocytosis may further activate the allergic reaction.
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In addition, sustained mucosal inflammation causes the cells to be susceptible to infection from bacteria
and viruses, resulting in strong antigen stimulation and further activation of the immune response.
The accumulation of these factors results in the activation of mast cells, which further increases IgE
levels. As such, we speculate that moderate or severe ECRS lesions may result in an increase in
mast cells positive for cytoplasmic IgE. In the present study, cytoplasmic IgE-positive mast cells were
significantly increased in moderate and severe ECRS, suggesting that the status of ECRS is primarily
allergic, involving activation of mast cells.
As an internal immune mechanism, mast cells are activated upon antigen stimulation to release
cytokines, such as IL-4, IL-13, and IL-5, which are classified as type 2 cytokines and are involved in the
production of IgE as well as the differentiation/proliferation of eosinophils, thus promoting eosinophil
expansion and production of IgE antibody by plasma cells. With increased severity of ECRS, mucosal
rupture may continuously occur, resulting in enhanced and sustained antigenic stimulation and further
mast cell activation, which subsequently cause an enhanced expression of FcεRI. Propagation of this
cycle is considered to lead to endocytosis of mast cells. In this study, since the patients’ blood samples
were not preserved due to the nature of the study being retrospective, it was not possible to quantify
Th2 cytokines in the blood. In addition, the quantification of these cytokines in tissues was not possible
due to the small amount of FFPE samples.
In addition, it has been reported that staphylococcal enterotoxin is likely to be involved
in eosinophilic inflammation of the nasal mucosa as a superantigen or as an adjuvant [18].
The staphylococcal enterotoxin of Staphylococcus aureus has been detected in NP and mucins, and
specific IgE against S. aureus enterotoxins has also been detected. Furthermore, the polyclonal increase
of nonspecific IgE in the nasal cavity is considered to be important for nasal polyp formation [19],
while also inducing differentiation of precursor cells to eosinophils and contributing to proliferation.
Furthermore, it has been reported that anti-IgE antibody therapy is an effective treatment for ECRS
accompanied by NP [20–22]. It has also been reported that anti-IL-5 antibodies were effective
against eosinophil-dominated NP [23]. IL-5 is an important cytokine for eosinophil migration and
activation. Taken together, it has been suggested that mast cells are involved in the mechanism of
ECRS accompanied by the formation of NP.
In a recent study, it has been reported that IgG4-positive cells increase significantly in severe
ECRS [24]. Particularly in allergic diseases, IgG4 is considered to act as a blocking agent for IgE
antibodies induced by the antigen. Furthermore, mast cells positive for cytoplasmic IgE have been
reported in IgG4-related disease (IgG4-RD) [17]. In addition, it has been shown that the number of
endocytic mast cells also increases in the lesions of IgG4-RD [17]. Severe cases of IgG4-RD often have
multiorgan lesions. Similarly, multiple organ lesions, such as eosinophilic esophagitis, have been
reported in severe cases of ECRS [25,26]. While the precise pathogenesis of these diseases is unclear,
there may be a link to family predisposition and allergic diseases [27,28].
In conclusion, it is suggested that mast cells that receive antigen stimulation are involved in the
pathogenesis of ECRS.
4. Materials and Methods
4.1. Patients
Seventy-one Japanese patients with CRS (47 males and 24 females; mean age, 55.8 years) were
enrolled. Among these, 57 patients exhibited NP, and the remainder demonstrated no visible NP
in the middle meatus (n = 14) [24]. Patients with CRSwNP were divided into non-ECRS (n = 27)
and ECRS (n = 30) groups based on the Japanese Epidemiological Survey of Refractory Eosinophilic
Chronic Rhinosinusitis (JESREC) criteria [5]. In brief, the JESREC scoring system assesses whether it is
a unilateral or bilateral disease, the presence of NP, degree of blood eosinophilia, and the dominant
shadow of ethmoid sinus in computed tomography (CT) scans. Herein, a case was diagnosed as ECRS
if it showed a JESREC score of ≥ 1, and tissue eosinophilia ≥ 70 per HPF; ×400). The severity of ECRS
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was further determined by the JESREC algorithm using factor A (presence of both blood eosinophilia
equal to or greater than 5% and an ethmoid-dominant shadow on a CT scan) and factor B (comorbid
bronchial asthma or nonsteroidal anti-inflammatory drug intolerance) as follows: cases negative for
both factor A and B, cases positive for either factor A or B, or cases positive for both factor A and B
were grouped into mild, moderate, or severe ECRS groups, respectively [5]. Using this algorithm, 30
ECRS patients were categorized as mild (n = 8), moderate (n = 12), or severe (n = 10) ECRS subgroups.
All CRSsNP patients were diagnosed as being non-ECRS using these criteria. During surgery, NP and
UT were taken from patients with CRSwNP and CRSsNP, respectively. Serum samples were collected
from 17 patients (non-ECRS: n = 6; mild ECRS: n = 4; moderate ECRS: n = 2; severe ECRS: n = 5).
As the control, 13 non-CRS patients (e.g., patients with blowout fractures, posterior ethmoidal cysts, or
sphenoidal cysts) with normal UT at inspection were enrolled (four males and nine females; mean age,
61.4 years). After surgery, CRS patients received medications, including macrolides and mucolytic
agents for 2 months, together with saline douching, which was continued as long as they could. In
addition, NP patients received systemic corticosteroids (prednisolone: started with 20 mg/day, then
gradually decreased over 1 month) followed by intranasal corticosteroids. Furthermore, ECRS patients
standardly received oral antileukotrienes.
Informed consent for participation in the study was obtained from each patient, and the study
was approved by the Human Research Committee of the Okayama University Graduate School of
Medicine and Dentistry (reference number 1505-030).
4.2. Histological Examination and Immunohistochemistry
All samples used in this study were surgically resected specimens. The surgically removed tissues
were fixed in 10% formaldehyde and embedded in paraffin. Serial 3-µm-thick sections were cut from
the blocks and stained with hematoxylin and eosin (H&E); the sections were immunohistochemically
stained using an automated BOND III stainer (Leica Biosystems, Wetzlar, Germany). Primary antibodies
against the following antigens were used: c-kit (diluted antibody; Nichirei Biosciences Inc., Tokyo,
Japan) and IgE (1:200; DAKO, Glostrup, Denmark).
4.3. Histological Evaluation of c-Kit and IgE-Positive Cell
Mast cells are defined as cells that express both high-affinity IgE receptors and the stem cell factor
receptor, c-kit; therefore, we analyzed the number of mast cells by immunostaining for these markers.
As dendritic cells also express FcεRI, they also stain positive for IgE immunohistochemistry; however,
their shape is significantly different from that of mast cells, allowing us to only quantify cells that could
be distinguished as mast cells.
Cell counts were performed by two independent researchers, and the average number was
calculated. The cells were counted in three hotspot fields with an HPF (×400), and the average per
field was determined. In the hotspot area of c-kit-positive cells, the number of c-kit-positive cells was
counted for each specimen. In the hotspot area of IgE-positive cells, the numbers of cells showing
IgE-positive in the membrane and cytoplasm were counted separately.
4.4. Statistical Analysis
Values are given as the median. The nonparametric Mann-Whitney U test was used to compare
data between groups, and Wilcoxon’s signed-rank test was used to analyze data within each group.
A Kruskal–Wallis test, followed by a Dunn test, was used for multiple comparisons. Correlation
analyses were performed using Spearman’s rank correlation. Statistical analyses were performed with
GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). The p-values for sensitivity
and specificity were calculated using JMP Pro 13.2 (SAS Institute Inc., Cary, NC, USA), and logistic
regression analyses were conducted using STATA 12.1 (StataCorp, College Station, TX, USA). A p value
less than 0.05 (two-tailed) was considered to be statistically significant.
Int. J. Mol. Sci. 2020, 21, 1843 12 of 13
To compare the c-kit-positive cells and IgE-positive cells among eosinophilic sinusitis, nonsinusitis,
chronic sinusitis, and noneosinophilic sinusitis, the Kruskal–Wallis test method, using IBM-SPSS
statistics software (version 24; IBM, Armonk, NY, USA), was applied. A p value < 0.05 was considered
statistically significant.
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